Cognition Therapeutics’ stock dips 43% following trial results for Alzheimer’s candidate
The company’s lead candidate, CT1812, for mild to moderate Alzheimer’s disease failed to show clinically significant change.
30 July 2024
30 July 2024
The company’s lead candidate, CT1812, for mild to moderate Alzheimer’s disease failed to show clinically significant change.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.